Corvel Corp
CRVLCorVel Corp (CRVL) is a provider of risk management and healthcare solutions, including claims management, medical networks, and utilization review services. The company focuses on delivering technology-driven services to insurance companies, employers, and government entities to improve healthcare outcomes and control costs. It leverages data analytics and a network of healthcare providers to streamline claims processing and manage risk effectively.
Company News
CorVel reported Q4 2026 earnings with quarterly revenue of $249 million (7% YoY increase) and EPS of $0.61 (up 19.6%). Full-year revenue reached $959 million with EPS of $2.14 (17% increase). The company secured multiyear contracts with top national payers, achieved 56% YoY growth in new bookings, and expanded RFP activity by 20%. Network Solutio...
CorVel reported Q3 2026 results with modest growth: revenue of $236 million (up 3% YoY) and EPS of $0.47 (up 2% YoY). The company highlighted strong operational metrics including 100% net revenue retention, 44% new business close rate, and meaningful AI-driven efficiency gains. Management attributed the modest results to short-term operational fa...
CorVel reported Q2 2026 financial results with $240 million revenue, a 7% increase from the previous year. The company highlighted significant investments in Agentic AI technology, workforce development through CorVel University, and strategic efforts to address labor market challenges in workers' compensation.
CorVel Corporation announced a three-for-one forward stock split, effective December 24, 2024. The additional shares will be distributed on the same date, and trading is expected to begin on a post-split basis on December 26, 2024.
CORXEL, a biotech company, has acquired the worldwide (excluding Greater China) rights to CX11, an oral small molecule GLP-1 receptor agonist, for the treatment of obesity and diabetes. CX11 has shown promising results in a Phase 2 clinical trial conducted in China and CORXEL plans to initiate a global Phase 2 study in 2025.
